Latest Breaking News On - Neoadjuvant durvalumab - Page 1 : comparemela.com

Perioperative Durvalumab Plus SOC Shows Promising EFS Results in Muscle-Invasive Urothelial Carcinoma

Treatment with neoadjuvant durvalumab plus gemcitabine and cisplatin followed by radical surgery and adjuvant durvalumab for patients with muscle-invasive urothelial carcinoma resulted in 2-year event-free survival rates that met the primary end point of the phase 2 SAKK 06/17 trial.

Swiss group for clinical cancer researchClinical oncologySwiss groupClinical cancer researchChronic kidney disease epidemiology collaborationNeoadjuvant durvalumabGemcitabine and cisplatinMuscle invasive urothelial carcinomaPhase 2 sakk 06 17 trial nct03406650

AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030

AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomBrendan mcevoyDaiichi sankyoSusan galbraithDave fredricksonNeoadjuvant durvalumabChelsea fordTrastuzumab deruxtecanA health systems approach toLung cancer policy networkLung ambition allianceBroad panelDaiichi sankyo incBreakthrough therapy designationInternational associationLung cancer

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Neoadjuvant durvalumabJohn heymachAdjuvant durvalumabPartnership withNon small cell lung cancerEarly stage lung cancerEarly stage nsclcDurvalumab therapyOverall survivalProgression free survivalEvent free survivalPathologic complete responsePd l1 expressionPd l1 levelAdverse eventsDrug adverse event

Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Recent updatesTranslating evidenceClinical practiceSmall cell lung cancerNeoadjuvant treatment strategiesLung cancerNon small cell lung cancerTrio therapyImmune checkpoint inhibitorsNeoadjuvant therapyPerioperative therapyNeoadjuvant chemotherapyCheckmate 816Nivolumab therapyNeoadjuvant nivolumabMolecular testing